(Q48852117)

English

The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy

scientific article published on 13 June 2011

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21671463

The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21671463

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jen-Kou Lin

1

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21671463

An-Jen Lin

2

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21671463

Chun-Chi Lin

3

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21671463

Yuan-Tzu Lan

4

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21671463

Shung-Haur Yang

5

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21671463

Anna Fen-Yau Li

6

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21671463

Shih-Ching Chang

7

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21671463

publication date

13 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21671463

Journal of Surgical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21671463

104

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21671463

6

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21671463

661-666

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21671463

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

PIK3CA cancer mutations display gender and tissue specificity patterns.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Molecular determinants of cetuximab efficacy

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Comparative genomic hybridization in hypotriploid/hyperdiploid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21993

21 January 2018

Identifiers

10.1002/JSO.21993

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21671463

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21671463

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48852117&oldid=2212089190"